Bull case
CervoMed is compelling because neflamapimod is showing a coherent mechanistic story across DLB and nfvPPA, with MRI, biomarker, and clinical signals suggesting it may address synaptic dysfunction and basal forebrain atrophy rather than only symptoms. The 159-patient RewinD-LB dataset, along with durable right basal forebrain volume stabilization over 48 weeks and improved connectivity measures, strengthens confidence that the program can meaningfully alter disease biology, while the ongoing Phase 2a nfvPPA study with 25 participants offers another near-term catalyst. Fundamental risk is also falling as the FDA removed the plasma exposure limit, the company secured a new 50mg tablet and controlled manufacturing process, and PK modeling supports a 100mg BID regimen with higher trough exposure and better dosing flexibility for future pivotal development.